BACKGROUND: Data on effectiveness of preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)-uninfected women attempting conception with HIV-infected male partners are limited to observational studies. METHODS: To explore the benefits of PrEP for conception, we developed a model to estimate the average annual probability of a woman remaining HIV-uninfected and having a child ("successful" outcome) via condomless sex with an HIV-infected male. The outcome likelihood is dependent upon parameters defining HIV-1 infectivity. We simulated 2 scenarios: optimal (condomless sex acts limited to the ovulation window), and suboptimal (acts not limited to ovulation). RESULTS: In the optimal scenario when the male is on antiretroviral therapy (ART), the average annual probability of the successful outcome is 29.1%, increasing to 29.2% with the addition of PrEP (P = .45). In the suboptimal scenario, the probability is 26.8% with ART alone versus 27.3% with ART/PrEP (P < .0001). Older maternal age reduces the probability of success in both scenarios, particularly after age 30. CONCLUSIONS: In our model, PrEP provides little added benefit when the HIV-infected male partner is on ART, condomless sex is limited to the ovulation window, and other modifiable transmission risks are optimized. Older female age decreases the probability of success by increasing the number of condomless sex acts required for conception.
BACKGROUND: Data on effectiveness of preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)-uninfectedwomen attempting conception with HIV-infected male partners are limited to observational studies. METHODS: To explore the benefits of PrEP for conception, we developed a model to estimate the average annual probability of a woman remaining HIV-uninfected and having a child ("successful" outcome) via condomless sex with an HIV-infected male. The outcome likelihood is dependent upon parameters defining HIV-1 infectivity. We simulated 2 scenarios: optimal (condomless sex acts limited to the ovulation window), and suboptimal (acts not limited to ovulation). RESULTS: In the optimal scenario when the male is on antiretroviral therapy (ART), the average annual probability of the successful outcome is 29.1%, increasing to 29.2% with the addition of PrEP (P = .45). In the suboptimal scenario, the probability is 26.8% with ART alone versus 27.3% with ART/PrEP (P < .0001). Older maternal age reduces the probability of success in both scenarios, particularly after age 30. CONCLUSIONS: In our model, PrEP provides little added benefit when the HIV-infected male partner is on ART, condomless sex is limited to the ovulation window, and other modifiable transmission risks are optimized. Older female age decreases the probability of success by increasing the number of condomless sex acts required for conception.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: James P Hughes; Jared M Baeten; Jairam R Lingappa; Amalia S Magaret; Anna Wald; Guy de Bruyn; James Kiarie; Mubiana Inambao; William Kilembe; Carey Farquhar; Connie Celum Journal: J Infect Dis Date: 2012-01-11 Impact factor: 5.226
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Rachelle J Chadwick; Joanne E Mantell; Jennifer Moodley; Jane Harries; Virginia Zweigenthal; Diane Cooper Journal: Top Antivir Med Date: 2011-11
Authors: R L Shapiro; M D Hughes; A Ogwu; D Kitch; S Lockman; C Moffat; J Makhema; S Moyo; I Thior; K McIntosh; E van Widenfelt; J Leidner; K Powis; A Asmelash; E Tumbare; S Zwerski; U Sharma; E Handelsman; K Mburu; O Jayeoba; E Moko; S Souda; E Lubega; M Akhtar; C Wester; R Tuomola; W Snowden; M Martinez-Tristani; L Mazhani; M Essex Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Ashley A Leech; James F Burgess; Meg Sullivan; Wendy Kuohung; Michal Horný; Mari-Lynn Drainoni; Cindy L Christiansen; Benjamin P Linas Journal: AIDS Date: 2018-11-28 Impact factor: 4.177
Authors: Carolyn M Audet; Erin Graves; Ezequiel Barreto; Caroline De Schacht; Wu Gong; Bryan E Shepherd; Arifo Aboobacar; Lazaro Gonzalez-Calvo; Maria Fernanda Alvim; Muktar H Aliyu; Aaron M Kipp; Heather Jordan; K Rivet Amico; Matthew Diemer; Andrea Ciaranello; Caitlin Dugdale; Sten H Vermund; Sara Van Rompaey Journal: Contemp Clin Trials Date: 2018-06-05 Impact factor: 2.226
Authors: Lealah C Pollock; Shannon Weber; Angela Kaida; Lynn T Matthews; Dominika L Seidman Journal: J Int AIDS Soc Date: 2017-07-26 Impact factor: 5.396
Authors: Sheree R Schwartz; Jean Bassett; Charles B Holmes; Nompumelelo Yende; Rebecca Phofa; Ian Sanne; Annelies Van Rie Journal: J Int AIDS Soc Date: 2017-03-08 Impact factor: 5.396
Authors: Carolyn M Audet; Erin Graves; Almiro M Emílio; Ariano Matino; Paula Paulo; Arifo M Aboobacar; Carlota L Fonseca; Sara Van Rompaey; Caroline De Schacht Journal: Contemp Clin Trials Commun Date: 2021-05-06